The lipoxygenase inhibitor used in our study which has been published 2006 in volume 18 of this journal (Shumilina E, Kiedaisch V, Akel A, Lang P, Hermle T, Kempe DS, Huber SM, Wieder T, Laufer S, Lang F. Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884. Cell Physiol Biochem. 2006;18(4-5):233-42) was named by mistake Bay-y-5884. This inhibitor (see formula) which was developed by Dr. Raddatz (Troponwerke, Cologne, Germany) has been synthesized by us.

It is the racemate of the enatiomer (-)-2(R)-Cycloheptyl-2-[4-(2-quinolylmethoxy)phenyl]-N-(methylsulfonyl)acetamide. The latter drug has been developed to phase I by Bayer Schering Pharma AG (Leverkusen, Germany) under the name Bay-y-1015 [1-3].

The drug of the Bayer AG which is named Bay-y-5884 is not a lipoxygenase inhibitor and completely unrelated to the substance used in our study.

References